Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Angion Biomedica Corp (NQ: ANGN )

1.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Angion Biomedica Corp

< Previous 1 2 3 Next >
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical... 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2022
Upgrades 
Via Benzinga
Angion Biomedica's Return On Capital Employed Overview
Benzinga Pro data, Angion Biomedica (NASDAQ:ANGN) reported Q1 sales of $1.65 million. Earnings fell to a loss of $14.24 million, resulting in a 195.63% decrease from last quarter. 
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Angion Biomedica: Q1 Earnings Insights
Angion Biomedica (NASDAQ:ANGN) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it... 
Via Benzinga
Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So
Via Benzinga
77 Biggest Movers From Yesterday
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate... 
Via Benzinga
Angion Biomedica's Return On Capital Employed Insights
According to Benzinga Pro, during Q4, Angion Biomedica (NASDAQ:ANGN) earned $14.89 million, a 194.82% increase from the preceding quarter. Angion Biomedica also posted a total of $25.94 million in... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
52 Biggest Movers From Friday
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its... 
Via Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors. Future... 
Via Benzinga
50 Biggest Movers From Friday
Gainers SigmaTron International, Inc. (NASDAQ: SGMA) jumped 84.7% to settle at $14.94 on Friday after the company reported Q2 EPS and sales results were higher year over year.... 
Via Benzinga
Mid-Afternoon Market Update: Dow Rises 150 Points; SigmaTron International Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.42% to 35,905.44 while the NASDAQ rose 0.34% to 15,570.02. The S&P also rose, gaining 0.66% to 4,698.21. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
36 Stocks Moving In Friday's Mid-Day Session
Gainers American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) jumped 43.1% to $2.6909. American Virtual Cloud Technologies shares jumped over 82% on Thursday after the company... 
Via Benzinga
Mid-Day Market Update: Oracle Gains Following Upbeat Q2 Results; Angion Biomedica Shares Drop
Midway through trading Friday, the Dow traded up 0.09% to 35,787.47 while the NASDAQ rose 0.11% to 15,534.76. The S&P also rose, gaining 0.38% to 4,685.15. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Morning Market Update: Markets Open Higher; Inflation Rate Increases To 6.8%
Following the market opening Friday, the Dow traded up 0.48% to 35,924.79 while the NASDAQ rose 0.47% to 15,579.93. The S&P also rose, gaining 0.60% to 4,695.55. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
Angion's ANG-3777 Faces Third Failure In 2021, This Time Flunks Acute Kidney Injury Trial
Angion Biomedica Corp (NASDAQ: ANGN) and Vifor Pharma shared results from the Phase 2 GUARD trial of Angion's ANG-3777 in cardiac surgery patients with... 
Via Benzinga
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
From Vifor Pharma
Via Business Wire
Mid-Afternoon Market Update: Nasdaq Surges Over 100 Points; Cortexyme Shares Plunge
Toward the end of trading Wednesday, the Dow traded down 0.23% to 35,674.01 while the NASDAQ rose 0.81% to 15,358.79. The S&P also rose, gaining 0.14% to 4,581.2. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
64 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
Mid-Day Market Update: Dow Falls Over 100 Points; Silicon Laboratories Shares Spike Higher
Midway through trading Wednesday, the Dow traded down 0.30% to 35,648.39 while the NASDAQ rose 0.32% to 15,283.97. The S&P also fell, dropping 0.03% to 4,573.51. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Did Angion Biomedica's Shares tumble Premarket Today?
After flopping a test in COVID-19 earlier this year, Angion Biomedica Corp's (NASDAQ: ANGN) lead candidate drug has hit a setback again, this time in kidney... 
Via Benzinga
Exposures COVID-19
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers China XD Plastics Company Limited (NASDAQ: CXDC) rose 139% to $1.40 in pre-market trading after jumping around 30% on Tuesday. Guardion Health Sciences, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.